Physician profile
Nancy Snow
NPI 1982337671
$1,098.13
in general payments reported to CMS, 2019-2025
19 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $30.11 · 2023: $232 · 2024: $434 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,068.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $300.34 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $227.48 | 2023-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $88.22 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $78.39 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $76.61 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $47.58 | 2024-2025 | Farxiga, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $30.11 | 2022 | |
| Sanofi-Aventis U.S. LLC | $28.64 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $27.99 | 2023 | Rexulti |
| Dexcom, INC. | $27.29 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $22.67 | 2023 | |
| Astellas Pharma US INC | $21.48 | 2025 | Veozah |
| Alnylam Pharmaceuticals INC. | $19.64 | 2024 | Givlaari |
| Janssen Pharmaceuticals, INC | $18.90 | 2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $18.89 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $17.23 | 2025 | Senza |
| Phathom Pharmaceuticals, INC. | $15.87 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $15.86 | 2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.94 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Snow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.